During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), discussion moderator Raoul S. Concepcion, MD, is joined by expert panelists David Crawford, MD, Jeffrey D. Dunn, PharmD, MBA, Michael Kolodziej, MD, and David Quinn, MD.
After the panelists briefly introduce themselves and explain their relationships to medical oncology, Dr Concepcion cites important statistics about the economic and clinical burden of CRPC.
Dr Quinn reviews the treatment landscape for CRPC and explains how a paradigm shift in the US Food and Drug Administration’s approval of agents to treat CRPC has improved the disease’s outlook.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More